Product Overview
[Drug Name]
Generic Name: Beraprost Sodium Tablets
Trade Name: Kaina
English Name: Beraprost Sodium Tablets
Chinese Pinyin: Beraprost Sodium Tablets
[Ingredients]
This product is a derivative of prostacyclin (PGI2)
[Properties]
Pale yellow film-coated tablets, engraved with "BS40" on one side, appearing white after removal of the coating.
[Indications]
Chronic arterial occlusive diseases such as Raynaud's disease, Raynaud's syndrome, chronic cerebral infarction, and other chronic arterial occlusive diseases.
[Dosage and Administration]
40 μg orally three times daily for six weeks as a course of treatment. Adults: 120 μg daily, divided into three doses after meals.
[Adverse Reactions]
Occasional adverse reactions include allergic reactions, headache, nausea, diarrhea, loss of appetite, increased liver function, facial flushing, and palpitations. Bleeding tendencies include cerebral hemorrhage, gastrointestinal bleeding, fundus hemorrhage, etc.; as well as facial flushing and headache.
[Contraindications]
This medication is contraindicated in pregnant women and patients with bleeding disorders. Use with caution in the following patients: those currently taking anticoagulants, antiplatelet drugs, or thrombolytics; women who are menstruating; and patients with a bleeding tendency or related conditions.
[Precautions]
This medication is contraindicated in pregnant women and patients with bleeding disorders. Use with caution in the following patients: those currently taking anticoagulants, antiplatelet drugs, or thrombolytics; women who are menstruating; and patients with a bleeding tendency or related conditions.
[Special Population Use]
Precautions for Children:
The safety of this medication in children has not been established (no experience).
Precautions for Pregnancy and Lactation:
This medication is contraindicated in pregnant women and should be used with caution in menstruating women.
Precautions for the Elderly:
The elderly should be careful with the dosage (physiological functions are generally reduced in the elderly).
[Drug Interactions]
Not yet known.
[Pharmacological Actions]
This product is a derivative of prostacyclin (PGI2). Among the various humoral factors synthesized by the blood vessel wall, prostaglandin (PGI2) is the earliest commercially available substance that regulates vascular tone and plays a vital role in maintaining blood flow to various tissues. It is the end product of an arachidonic acid chain reaction and possesses potent antiplatelet and vasodilatory effects. Produced primarily through arachidonic acid metabolism in the blood vessel wall, PGI2 is produced not only by endothelial cells but also by vascular smooth muscle cells, exerting a potent vasodilatory effect. It is known that PGI2 synthesis is reduced in areas of arteriosclerosis. Reports indicate that apolipoprotein A-I, the FGI2-stabilizing factor, is decreased in ischemic heart disease, acute myocardial infarction associated with coronary artery spasm, and unstable angina. PGI2 has an exoenol ether structure. Due to its extremely unstable chemical properties and rapid decomposition in neutral solutions and within the body, its use is limited to conditions that can be treated with intravenous drips. This product replaces the exoenol structure with a phenol and chemically modifies the ω side chain to enhance its activity and stability. This product is an orally available prostacyclin derivative with potent vasodilatory and antiplatelet effects.
Storage: Protect from light and store tightly closed.
Specifications: 40µg x 10 tablets
Packaging: Box
Expiration Date: 24 months
Approval Number: National Medicine Standard H20083589
Manufacturer: Beijing Taide Pharmaceutical Co., Ltd.
